Human Longevity Extends $1M Cancer Pledge to Lung Cancer--Betting Big on AI-Driven Early Detection
Company reiterates its precision prevention commitment with latest expansion of its high-stakes cancer pledge—now targeting lung cancer, the world's deadliest cancer.
SOUTH SAN FRANCISCO, Calif., July 31, 2025 /PRNewswire/ -- Inaboldmove to challenge one of the deadliestcancersworldwide, Human Longevity, Inc. (HLI) is expanding its high-profile $1 million pledge to include late-stage lung cancer—sending a clear signal that precision prevention is not just a promise, but a guarantee. Reflecting HLI's unwavering belief in early detection and the power of precision diagnostics, this initiative will offer up to $1 million in clinical support for any qualified member diagnosed with late-stage lung cancer while actively participating in HLI's Executive Health Program or affiliated 100+ Longevity Programs.
Through its ExecutiveHealthProgram and 100+ Longevity Programs, Human Longevity has screened over 10,000 members using a comprehensive, AI-driven platform that integrates genomics, imaging, and longitudinal biomarker tracking . The addition of lung cancer to HLI's pledge program reinforces its commitment to detecting cancers earlier—when treatment is most effective.
This precision strategy includes:
- Whole genome sequencing with hereditary cancer risk assessment
- Whole-body and volumetric MRI + other imaging testing
- Multi-cancer early detection (MCED) blood tests
- Continuous respiratory symptom and biomarker monitoring
This integrated approach—offered exclusively through HLI's ExecutiveHealthProgram —enables the detection of lung cancer earlier and with greater confidence, empowering members with proactive and personalized care.
How the Initiative Works
Eligible participants must be continuously enrolled in the ExecutiveHealthProgram or 100+ Longevity Programs, and must complete our pledge and annual lung cancer-specific screenings, including MCED testing and clinical assessments, as part of their protocol. If a participating member is diagnosed with late-stage lung cancer during active membership, HLI will provide up to $1 million in clinical navigation, treatment coordination, and consultation with top thoracic oncology experts .
"With our integrated screening tools and AI - poweredriskanalysis , we're transforming how we detect and respond to life-threatening diseases like lung cancer," said Dr. Wei - WuHe , Executive Chairman of Human Longevity, Inc. "This pledge reinforces our promise to help our members stay ahead of disease and receive world-class care in every scenario."
Lung cancer is the leading cause of cancer-related death globally, often diagnosed in later stages due to subtle or absent early symptoms. By combining advanced imaging, genomic insights, and real-time biomarker data, Human Longevity is redefining what's possible in early lung cancer detection and preventative care.
This pledge is more than a commitment—it's a strategic expansion of Human Longevity's mission to shift healthcare from reactive to proactive. It ensures members benefit from the most advanced diagnostic tools, clinical pathways, and personalized care plans available today.
Media Contact:
media@humanlongevity.com
https://www.humanlongevity.com/1mlung
Human Longevity, Inc. is a biotechnology company at the forefront of integrating genomics, AI, and multimodal diagnostics to extend human healthspan. Through its flagship Executive Health Program and 100+ Longevity Programs, HLI delivers comprehensive, data-driven evaluations aimed at identifying and preventing disease long before symptoms arise. To learn more or how to enroll, visit https://www.humanlongevity.com/1mlung.
View original content to download multimedia:https://www.prnewswire.com/news-releases/human-longevity-extends-1m-cancer-pledge-to-lung-cancerbetting-big-on-ai-driven-early-detection-302519105.html
SOURCE Human Longevity, Inc.